Should You Buy The Dip In Alnylam Stock

For questions about this article or underlying research, email [email protected].

Alnylam Pharmaceuticals (ALNY) stock closed at $165 on October 30, 2026, 29.5% below its October 15 close. Most of that fall came on October 29, the day Alnylam reported its third quarter and management said it was not yet satisfied with demand growth; the shares lost 25.1% that day. A fall that fast tempts buyers. So has a drop this deep in Alnylam usually been a chance to buy?

Alnylam Stock Ended Higher After Four Of Nine Drops

Less than half the time, for a buyer who held for a year. Since 2010, Alnylam stock has fallen more than 30% over 30 trading days on nine earlier occasions. Twelve months after those drops, the shares were higher in four of them. The median result a year later was a 1.0% fall, though the outcomes ran from a 47% loss after the January 2016 drop to a 239% gain after the October 2016 drop. Three months after a drop, the shares were higher in eight of the nine cases, yet only four were still higher at twelve months.

Holding on also meant sitting through lower prices. At the median, the lowest close in the year after a drop was 22.6% below the close on the day of the drop. The highest price in that year came a median of 199 days after the drop, about six and a half months in.

Alnylam Still Grows Sales And Generates Cash

Alnylam's revenue was $1.46 billion in the third quarter of 2026, up 16.7% from a year earlier. That marked its slowest growth of the past five quarters. Sales of its drugs grew faster. Product revenues rose 52%, management said on the October 29 call. Collaboration revenue fell, mainly because the year-earlier quarter included a one-time $300 million milestone from Roche.

Alnylam's operating margin was 23.7% in the quarter, against 29.5% in the same quarter a year earlier, when that Roche payment was part of revenue. Its operations brought in cash in each of the past five quarters. At September 30, Alnylam held $2.33 billion more in cash and short-term investments than it owed in debt. After the drop, the shares trade at 4.4 times Alnylam's sales over the past twelve months, against 3.2 times for the S&P 500.

Management Says Patient Starts Are Slower Than Hoped

Management said on the October 29 call that many of the newer doctors prescribing AMVUTTRA have fewer cardiomyopathy patients, and their prescribing habits take time to change. Alnylam now expects 2026 sales of AMVUTTRA and ONPATTRO to land at the low end of its $4.2 billion to $4.5 billion range. For the fourth quarter, management expects U.S. inventory and price to hold back reported growth. Its outlook allows for hospitals ordering cautiously while they await a final rule on the 340B drug discount program, which management called a meaningful portion of its business.

A buyer after this drop gets a company that is growing its drug sales, earning an operating profit, and holding more cash than debt. Its pipeline includes brezosiran, an experimental Huntington's disease drug with positive initial Phase 1b data reported on October 23. That buyer also gets a stock whose deep drops have been followed by a higher price a year later less than half the time. Buying now means believing that the slower patient starts management described will pick up. Alnylam's 2027 product revenue guidance, due with its fourth-quarter results in February 2027, is the number to watch.

How To Act On ALNY?

Now you know Alnylam Pharmaceuticals better. Our purpose is to inform you so you can decide for yourself, and acting on one stock, in either direction, carries its own risk.

If you would rather own a portfolio built to spread that risk, the Trefis High Quality (HQ) Portfolio holds 30 quality companies in equal weight. Since its inception in September 2020 it has returned 105%, ahead of a benchmark that combines the S&P 500, S&P Mid-cap and Russell 2000.

See How The HQ Portfolio Works

Spot an error or want more like this? Tell us in 10 seconds.